Biotransformation Flashcards

1
Q

Consequences of biotransformation

A

activation of pro-drug

active compound–>active compound

inactivation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Sites of biotransformation

A

liver mainly

also GI, lungs, skin, kidneys

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the first-pass effect

A

oral drugs absorbed in SI–>liver–> hepatic portal system-> extensive metabolism

***limits bioavailability of some drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What drugs have bioavailability increased via GI flora?

A

estrogens used in contraception d/t recycling of metabolites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is an example of a drug that undergoes extensive first pass biotransformation and only 25% reaches blood?

A

morphine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Is phase 1 of metabolism catabolic or anabolic

A

catabolic–>inactivates drug via unmasking functional group to make it polar

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Where are phase 1 enzymes located

A

lipophilic ER membranes of liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the function of phase 2

A

conjugate–>more excretable

ex: glucuronidation

anabolic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What phase do CYPs work in

A

phase 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What CYP is involved in 50% drug metabolism

A

CYP 3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What CYPs are most important

A

1A2

2A6

2D6

2E1

3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Where do CYPs get their reducing power

A

NADPH (use O2 and H to oxidize drugs and make polar)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Genetic defect in pseudocholinesterase has what effect

A

metabolize succinylcholine 50% the rate as normal people

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why can AR trait, which has decrease in N-acetyltransferase, cause hepatotoxicity?

A

caffeine, isoniazid, hydralazine metabolized at slower rates since less enzyme–> builds up in liver and causes hepatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What enzymes are involved in phase 1

A

CYPs
FMO
hydrolases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are phase 2 enzymes

A

transferases

17
Q

Inducer examples

A

phenobarbital

chronic ethanol

tobacco smoke (aromatic hydrocarbons)

rifampin

St John’s wort

18
Q

What do inducers do to drug levels

A

activate enzymes, so less drug in body

19
Q

What happens to clearance with inducers?

A

inducers decrease half-life, so clearances increases

20
Q

Prominent inhibitors

A

grapefruit juice

allopurinol and mercaptopurine given together–> increases merc. toxicity

21
Q

What is the grapefruit juice effect

A

grapefruit with drugs can irreversibly inhibit CYP 3A4

22
Q

What makes neonates highly susceptible to drug toxicity

A

underdeveloped BBB, weak biotransforming activity, immature excretion

23
Q

What is the most important factor for decreased drug metabolism in elderly

A

liver and kidney disease

not really drug dependent d/t half-life

24
Q

Give example of biotransformation to toxic product

A

acetaminophen-induced hepatotoxicity

intake exceeds therapeutic dose, GSH in liver is depleted faster than regenerated–> toxic metabolites accumulate

25
Explain polymorphism in CYP 2D6
codeine--> morphine (200 x agonist) normally if polymorphism, insufficient pain relief and increased risk for side effects (resp depression, drowsiness)
26
Explain polymorphism in CYP 2C 19
decreases active metabolite formation and reduces Clopidogrel's antiplatelet activity --> severe risk for cardiovascular events
27
Explain polymorphism in G6PD
hemolysis when using drugs for lowering uric acid
28
Phase 0
microdosing to human volunteers
29
Phase 1
25-50 people aware what testing is being conducted absorption, half life, metabolism
30
Phase 2
100-200 people single blind (physician knows) placebo, dosing requirements, efficacy, toxicities
31
Phase 3
300-3000 people safety crossover and double blind
32
Phase 4
after market approval monitor in population